COVID-19 scenario and recommendations on the continuity of immunobiological therapy in patients with atopic asthma in Brazil and Latin America

References

• Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720.
   PubMed Web of Science ®Google Scholar
• Kimura H, Francisco D, Conway M, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol. 2020;146(80–88.e8):80–88.e8.
   PubMedGoogle Scholar
• Wang Y, Ao G, Qi X, et al. The association between COVID-19 and asthma: a systematic review and meta-analysis. Clin Exp. 2020;50:1274–1277.
   PubMed Web of Science ®Google Scholar
• Liu S, Cao Y, Du T, et al. Prevalence of comorbid asthma and related outcomes in COVID-19: a Systematic Review and Meta-Analysis. The Journal of Allergy and Clinical Immunology in Practice. 2021;9:693–701.
   PubMed Web of Science ®Google Scholar
• Castillo JR, Peters SP, Busse WW. Asthma Exacerbations: pathogenesis, Prevention, and Treatment. The Journal of Allergy and Clinical Immunology in Practice. 2017;5:918–927.
   PubMed Web of Science ®Google Scholar
• Alkan SS. Legends of allergy/immunology: Georges Köhler and the discovery of monoclonal antibodies. Allergy. 2019;74:1412–1414.
   PubMed Web of Science ®Google Scholar
• Biologics CL. Allergy immunotherapy in the treatment of allergic diseases. Immunol Allergy Clin North Am. 2020;40:687–700.
   PubMed Web of Science ®Google Scholar
• Ozdemir C. Monoclonal antibodies in allergy: updated applications and promising trials. Recent Pat Inflamm Allergy Drug Discov. 2015;9:54–65.
   PubMed Web of Science ®Google Scholar
• Lee T, Nair P, Corrigan CJ. Review of monoclonal antibody therapies in asthma and allergic diseases - a new paradigm for precision medicine. Asian Pac J Allergy Immunol. 2020;38:78–90.
   PubMed Web of Science ®Google Scholar
• Kröker A, Tirzīte M. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. Respir Res. 2021;22:304.
   PubMed Web of Science ®Google Scholar
• JBI manual for evidence synthesis. JBI Manual for Evidence Synthesis. JBI; 2020.
   Google Scholar
• Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020;382:1199–1207.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
   PubMed Web of Science ®Google Scholar
• Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. Jama. 2020;323(14):1406–1407.
   PubMed Web of Science ®Google Scholar
• Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020;382:1177–1179.
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): a Review. Jama. 2020;324:782–793.
   PubMed Web of Science ®Google Scholar
• Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172:577–582.
   PubMed Web of Science ®Google Scholar
• Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;250–256. DOI:https://doi.org/10.1002/jmv.26232
   Google Scholar
• Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 — COVID-NET, 14 States, March 1–30, 2020. MMWR. Morbidity and Mortality Weekly Report
   Google Scholar
• Gao Y, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID‐19 patients: a review. Allergy. 2021;76:428–455.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(271–280.e8):271–280.e8.
   PubMedGoogle Scholar
• Gupta A, Madhavan M, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nature Medicine. 2020;Vol. 26:1017–1032.
   PubMed Web of Science ®Google Scholar
• Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–469.
   PubMed Web of Science ®Google Scholar
• Ritchie H, Ortiz-Ospina E, Beltekian D, et al. Coronavirus Pandemic (COVID-19) [Internet]. Our World in Data. 2020 cited 2021 Mar 13. Available from: https://ourworldindata.org/coronavirus.
   Google Scholar
• Pfefferbaum B, North CS. Mental health and the Covid-19 pandemic. N Engl J Med. 2020;383:510–512.
   PubMed Web of Science ®Google Scholar
• Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord. 2020;277:55–64.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396:1979–1993.
   PubMed Web of Science ®Google Scholar
• Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369:77–81.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–192.
   PubMed Web of Science ®Google Scholar
• Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397(10279):1057–1058.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615.
   PubMed Web of Science ®Google Scholar
• Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397:1178–1181.
   PubMed Web of Science ®Google Scholar
• Bos R, Rutten L, van der Lubbe JEM, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020;5:91.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Le Gars M, Shukarev G, et al. interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021 [January 13];384:1824–1835.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187–2201.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479–488.
   PubMed Web of Science ®Google Scholar
• De Monchy JG, Demoly P, Akdis CA, et al. Allergology in Europe, the blueprint. Allergy: Eur J Allergy Clin Immunol. 2013;68:1211–1218.
   Google Scholar
• Blumenthal KG, Peter JG, Trubiano JA, et al. Antibiotic allergy. Lancet. 2019;393:183–198.
   PubMed Web of Science ®Google Scholar
• Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6:761–771.
   PubMed Web of Science ®Google Scholar
• Palomares O, Akdis M, Martín-Fontecha M, et al. Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. Immunol Rev. 2017;278:219–236.
   PubMed Web of Science ®Google Scholar
• Taketomi EA, Miranda JS, Jp Da C-J, et al. Allergen-specific immunotherapy follow-up by measuring allergen-specific IgG as an objective parameter. Immunotherapy - Myths, Reality, Ideas, Future. InTech; 2017. p. 382–401.
   Google Scholar
• Hatzler L, Hofmaier S, Papadopoulos NG. Allergic airway diseases in childhood - marching from epidemiology to novel concepts of prevention. Pediatr Allergy Immunol. 2012;23:616–622.
   PubMed Web of Science ®Google Scholar
• Shpakou A, Brozek G, Stryzhak A, et al. Allergic diseases and respiratory symptoms in urban and rural children in Grodno Region (Belarus). Pediatr Allergy Immunol. 2012;23:339–346.
   PubMed Web of Science ®Google Scholar
• Arrieta M-C, Stiemsma LT, Dimitriu PA, et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci Transl Med. 2015;7:307ra152.
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H. The immunology of the allergy epidemic and the hygiene hypothesis. Nat Immunol. 2017;18:1076–1083.
   PubMed Web of Science ®Google Scholar
• Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246.
   PubMed Web of Science ®Google Scholar
• Pawankar R, Canonica G, and Holgate S, et al. WAO white book on allergy. Milwaukee: World Allergy Organization (WAO); 2013. Update.
   Google Scholar
• Keil T, Bockelbrink A, Reich A, et al. The natural history of allergic rhinitis in childhood. Pediatr Allergy Immunol. 2010;21:962–969.
   PubMed Web of Science ®Google Scholar
• Ziyab AH. Prevalence and risk factors of Asthma, Rhinitis, and Eczema and Their Multimorbidity among Young Adults in Kuwait: a cross-sectional study. Biomed Res Int. 2017;2017:2184193.
   PubMed Web of Science ®Google Scholar
• Ardusso LRF, Neffen HE, Fernandez-Caldas E, et al. Environmental intervention in respiratory disease. Medicina (B Aires). 2019;79(2):123–136.
   PubMed Web of Science ®Google Scholar
• Sur DKC, Plesa ML. Treatment of Allergic Rhinitis. Am Fam Physician. 2015;92(11):985–992.
   PubMed Web of Science ®Google Scholar
• Ellis AK, Frankish CW, O’Hehir RE, et al. Treatment with grass allergen peptides improves symptoms of grass pollen–induced allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2017;140:486–496.
   PubMed Web of Science ®Google Scholar
• Shamji MH, Ceuppens J, Bachert C, et al. Lolium perenne peptides for treatment of grass pollen allergy: a randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol. 2018;141:448–451.
   PubMed Web of Science ®Google Scholar
• Boonpiyathad T, Sokolowska M, Morita H, et al. Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy. Allergy. 2019;74:976–985.
   PubMed Web of Science ®Google Scholar
• Caffarelli C, Mastrorilli C, Procaccianti M, et al. Use of sublingual immunotherapy for aeroallergens in children with Asthma. J Clin Med. 2020;9:3381.
   Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573–582.
   PubMed Web of Science ®Google Scholar
• Chiarella SE. Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria. Allergy Asthma Proc. 2019;40:485–489.
   PubMed Web of Science ®Google Scholar
• Poulakos MN, Cargill SM, Waineo MF, et al. Mepolizumab for the treatment of severe eosinophilic asthma. Am J Health Syst Pharm. 2017;74:963–969.
   PubMed Web of Science ®Google Scholar
• Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11:467–474.
   PubMed Web of Science ®Google Scholar
• Walsh GM. Reslizumab in the treatment of severe eosinophilic asthma: an update. Immunotherapy. 2018;10:695–698.
   PubMed Web of Science ®Google Scholar
• Dávila González I, Moreno Benítez F, Benralizumab: QS. A new approach for the treatment of severe eosinophilic asthma. J Investig Allergol Clin Immunol. 2019;29:84–93.
   PubMed Web of Science ®Google Scholar
• Marone G, Spadaro G, Braile M, et al. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. Expert Opin Investig Drugs. 2019;28:931–940.
   PubMedGoogle Scholar
• Chen YL, Gutowska-Owsiak D, Hardman CS, et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. In: Science Translational Medicine. 2019. p. 11.
   Google Scholar
• Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy: Eur J Allergy Clin Immunol. 2020;75:1730–1741.
   Google Scholar
• Yang JM, Koh HY, Moon SY, et al. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J Allergy Clin Immunol. 2020;146:790–798.
   PubMed Web of Science ®Google Scholar
• Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, march 1- 30, 2020. MMWR. Morbidity and Mortality Weekly Report. 2020;69:458–464.
   PubMed Web of Science ®Google Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436.
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323:2052–2059.
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Busse WW, Bacharier LB, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146(203–206.e3). DOI:https://doi.org/10.1016/j.jaci.2020.04.009.
   Google Scholar
• Sajuthi SP, DeFord P, Li Y, et al. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. Nat Commun. 2020;11:5139.
   PubMed Web of Science ®Google Scholar
• Du Y, Tu L, Zhu P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med. 2020;201:1372–1379.
   PubMed Web of Science ®Google Scholar
• Ferastraoaru D, Hudes G, Jerschow E, et al. Eosinophilia in Asthma patients is protective against severe COVID-19 Illness. J Allergy Clin Immunol Pract. 2021;9:1152–1162.e3.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Diaz SN, Martin B, Villarreal-Gonzalez RV, et al. Psychological impact of the COVID-19 pandemic on patients with allergic diseases. World Allergy Organ J. 2021;14:100510.
   PubMed Web of Science ®Google Scholar
• Cardinale F, Ciprandi G, Barberi S, et al. Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic. Ital J Pediatr. 2020;46:1–14.
   PubMed Web of Science ®Google Scholar
• The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2021;384:693–704.
   PubMed Web of Science ®Google Scholar
• Ghanei M, Solaymani-Dodaran M, Qazvini A, et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respir Res. 2021;22:22.
   PubMed Web of Science ®Google Scholar
• Singh K, Kumar S, Shastri S, et al. Black fungus immunosuppressive epidemic with Covid-19 associated mucormycosis (zygomycosis): a clinical and diagnostic perspective from India. Immunogenetics. 2021;1:1.
   Google Scholar
• Lansbury L, Lim B, Baskaran V, et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):266–275.
   PubMed Web of Science ®Google Scholar
• Liu W-D, Wang J-T, Hung -C-C, et al. Accelerated progression of pulmonary tuberculosis in a COVID-19 patient after corticosteroid treatment. J Microbiol Immunol Infect. 2021. DOI:https://doi.org/10.1016/j.jmii.2021.08.007.
   Google Scholar
• Shionoya Y, Taniguchi T, Kasai H, et al. Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: a retrospective study. PloS One. 2021;16(9):e0256977.
   PubMed Web of Science ®Google Scholar
• Neurath MF. COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nat Clin Pract Gastroenterol Hepatol. 2021;18:1.
   Google Scholar
• Lukin DJ, Kumar A, Hajifathalian K, et al. Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease. Gastroenterology. 2020;159:1541.
   PubMed Web of Science ®Google Scholar
• Chavasse R, Almario A, Christopher A, et al. The Indirect impact of COVID-19 on children with asthma. Archivos de Bronconeumología. 2020;56:768–769.
   PubMed Web of Science ®Google Scholar
• Abe K, Miyawaki A, Nakamura M, et al. Trends in hospitalizations for asthma during the COVID-19 outbreak in Japan. J Allergy Clin Immunol. 2021;9:494–496.e1.
   Web of Science ®Google Scholar
• Pelletier JH, Rakkar J, Au AK, et al. Trends in US pediatric hospital admissions in 2020 compared with the decade before the COVID-19 pandemic. JAMA Network Open. 2021;4:e2037227–e2037227.
   PubMed Web of Science ®Google Scholar
• Levene R, Fein DM, Silver EJ, et al. The ongoing impact of COVID-19 on asthma and pediatric emergency health-seeking behavior in the Bronx, an epicenter. Am J Emerg Med. 2021;43:109.
   PubMedGoogle Scholar
• Ozturk AB, Baççıoğlu A, Soyer O, et al. Change in allergy practice during the COVID-19 Pandemic. Int Arch Allergy Immunol. 2021;182:49–52.
   PubMed Web of Science ®Google Scholar
• Koca Kalkan I, Hale Ates KA, et al. Real-life adherence to subcutaneous immunotherapy: what has changed in the era of the COVID-19 pandemic. World Allergy Organ J. 2021;14.
   Web of Science ®Google Scholar
• Kendirlinan R, Cerci P, Mungan D. Skin prick test practice in allergy clinics during coronavirus disease 2019 pandemic. Ann Allergy Asthma Immunol. 2021;127:272–274.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Agache I, Bonini M, et al. COVID-19 pandemic and allergen immunotherapy- an EAACI survey. Allergy. 2021;00:38.
   Google Scholar
• Kitazawa H, Hizawa N, Nishimura Y, et al. The impact of the COVID-19 pandemic on asthma treatment in Japan: perspectives based on doctors’ views. Respir Investig. 2021;59:670–674.
   PubMed Web of Science ®Google Scholar
• Crespo-Lessmann A, Plaza V, Almonacid C. Multidisciplinary consensus on sputum induction biosafety during the COVID-19 pandemic. Allergy. 2021;76:2407–2419.
   PubMed Web of Science ®Google Scholar
• Ferraro VA, Zamunaro A, Spaggiari S, et al. Pediatric asthma control during the COVID‐19 pandemic. Immun Inflamm Dis. 2021;9:561.
   PubMed Web of Science ®Google Scholar
• Matucci A, Caminati M, Vivarelli E, et al. COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: results from a multicenter Italian survey. Allergy. 2021;76:871–874.
   PubMedGoogle Scholar
• Ferrante G, Licari A, Marseglia GL, et al. Digital health interventions in children with asthma. Clin Exp Allergy. 2021;51:212–220.
   PubMed Web of Science ®Google Scholar
• Glover RE, Urquhart R, and Lukawska J, et al. Vaccinating against covid-19 in people who report allergies. Bmj. 2021;120:372.
   Google Scholar
• Ring J, Beyer K, Biedermann T, et al. Messages for patients and relatives from the 2021 update of the guideline on acute therapy and management of anaphylaxis. Allergo J Int. 2021;30:1–6.
   PubMedGoogle Scholar
• Klimek L, Pfaar O, Hamelmann E, et al. COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for applied allergology (AeDA) and the German society for allergology and clinical immunology (DGAKI). Allergol Select. 2021;5:251–259.
   PubMedGoogle Scholar
• Caminati M, Guarnieri G, Batani V, et al. COVID-19 vaccination in patients with severe asthma on biologic treatment: safety, tolerability, and impact on disease control. Vaccines (Basel). 2021;9:853.
   PubMed Web of Science ®Google Scholar
• Smola A, Samadzadeh S, Müller L, et al. Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35:e743–e745.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Klimek L, Hamelmann E, et al. COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) – a position paper of the German society of allergology and clinical immunology (dgaki) and the German society for applied allergology (AeDA). Allergol Select. 2021;5:140.
   PubMedGoogle Scholar
• Vultaggio A, Agache I, Akdis CA, et al. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement. Allergy. 2020;75:2764–2774.
   PubMed Web of Science ®Google Scholar
• Dreher M, Kersten A, Bickenbach J, et al. The characteristics of 50 hospitalized COVID-19 patients with and without ARDS. Dtsch Arztebl Int. 2020;117:271–278.
   PubMed Web of Science ®Google Scholar
• Dong X, Cao Y, Lu X, et al. Eleven faces of coronavirus disease 2019. Allergy. 2020;75:1699–1709.
   PubMed Web of Science ®Google Scholar
• Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Jama. 2020;323:1574–1581.
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, and Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75:1023–1042.
   PubMed Web of Science ®Google Scholar
• Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1058–1068.
   PubMed Web of Science ®Google Scholar
• Criado PR, Pagliari C, and Criado RFJ, et al. What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2? Dermatol Ther. 2020:6:33.
   Google Scholar
• Esquivel A, Busse WW, Calatroni A, et al. Effects of Omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. Am J Respir Crit Care Med. 2017;196:985–992.
   PubMed Web of Science ®Google Scholar
• Lommatzsch M, Stoll P, Virchow JC. COVID-19 in a patient with severe asthma treated with Omalizumab. Allergy. 2020;75:2705–2708.
   PubMed Web of Science ®Google Scholar
• Ricardo JW, Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther. 2020;33:e13687.
   PubMed Web of Science ®Google Scholar
• Shaker MS, Oppenheimer J, Grayson M, et al. COVID-19: pandemic contingency planning for the allergy and immunology clinic. The Journal of Allergy and Clinical Immunology in Practice. 2020;8:1477–1488.e5.
   PubMed Web of Science ®Google Scholar
• WHO. WHO preferred product characteristics of monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease. Geneva PP - Geneva: World Health Organization; 2021.
   Google Scholar
• Atiqi S, Hooijberg F, Loeff FC, et al. Immunogenicity of TNF-Inhibitors. Front Immunol. 2020;11:312.
   PubMed Web of Science ®Google Scholar
• Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7:e00535.
   PubMed Web of Science ®Google Scholar
• Allergic patients during COVID-19 pandemic [Internet]. World Allergy Organization. 2020 cited 2021 May 11]. Available from 2021 May 11: https://www.worldallergy.org/UserFiles/file/Allergic_patients_during_COVID-19.pdf.
   Google Scholar
• Shaker MS, Oppenheimer J, Grayson M, et al. COVID-19: pandemic Contingency Planning for the Allergy and Immunology Clinic. J Allergy Clin Immunol Pract. 2020;8:1477–1488.e5.
   PubMed Web of Science ®Google Scholar
• Resolutions: staying COVID free keeping allergy and asthma symptoms under control [Internet]. ACAAI (American College of Allergy Asthma and Immunology). 2020 cited 2021 May 11]. Available from 2021 May 11: https://acaai.org/news/resolutions-2021-staying-covid-free-keeping-allergy-and-asthma-symptoms-under-control.
   Google Scholar
• [ASBAI makes recommendations for asthma patients in the face of coronavirus pandemic] Portuguese [Internet]. Brazilian Association of Allergy, Asthma and Immunology (ASBAI). 2020 Accessed 11 May 2021. Available from: https://asbai.org.br/asbai-faz-recomendacoes-para-pacientes-com-asma-diante-da-pandemia-do-coronavirus/.
   Google Scholar
• [The Brazilian Association of Allergy and Immunology (ASBAI). supports and disseminates the position of the Latin American Society (SLAAI) on the relationship between COVID-19 and asthma] Portuguese [Internet]. Brazilian Association of Allergy, Asthma and Immunology (ASBAI). 2020 Accessed 11 May 2021. Available from: https://asbai.org.br/a-associacao-brasileira-de-alergia-e-imunologia-asbai-apoia-e-divulga-o-posicionamento-da-sociedade-latina-americana-slaai-sobre-a-relacao-entre-covid-19-e-asma/
   Google Scholar
• Villa L, Cavallo MC, Crisci MS, et al. [General recommendations of the practice of the allergy and clinical immunology during the COVID-19 pandemic in Argentina] Spanish [Internet]. Argentinian Association of Allergy and Clinical Immunology. 2020 cited 2021 May 11]. Available from 2021 May 11: https://alergia.org.ar/index.php/institucional/sobre-aaaeic/newsletter/recomendaciones-generales-2.
   Google Scholar
• [Asthma and asthma medication in COVID-19 times] Spanish [Internet]. Colombian Association of Allergy, Asthma and Immunology. 2020 [cited 2021 May 11]. Available from: https://acaai.co/asma-y-medicacion-para-el-asma-en-tiempos-de-covid-19/.
   Google Scholar